Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natus set to purchase brain monitoring technology

This article was originally published in Clinica

Executive Summary

Diagnostics firm Natus Medical is set to boost its newborn brain injury products portfolio with the purchase of New Zealand-based bedside brain monitoring company BrainZ Instruments. The deal, expected to close in early November 2008, will see Natus acquire all the trading assets of Auckland-based BrainZ, including the BRM2 and BRM3 monitoring devices for newborns and the RecogniZe detection system for NZ$1.3m ($800,000). Natus will also undertake the various distribution agreements for the technology it has acquired. The San Carlos, California-based firm expects this acquisition to be accretive to earnings in the first full quarter following the deal. Natus’ existing newborn brain injury products include the Olympic CFM 6000 bedside cerebral function monitor.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel